Hyponatremia associated with Ipilimumab-induced hypophysitis

Med Oncol. 2012 Mar;29(1):374-7. doi: 10.1007/s12032-010-9794-7. Epub 2011 Jan 25.

Abstract

A 75-year-old woman with a history of stage IV metastatic melanoma underwent treatment with the CTLA-4 blocking agent Ipilimumab. She presented 2 months after initiating treatment with a severe headache. Laboratories were consistent with severe hyponatremia. MRI of the brain revealed enlargement of the pituitary gland, enhancement of the infundibulum, and an enhancing, centrally necrotic foci in the anterior pituitary. Based on the clinical and radiographic findings, she was diagnosed with treatment-related syndrome of inappropriate antidiuretic hormone secretion (SIADH). Effective treatment consisted of fluid restriction, hyperosmolar therapy, and steroids.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Hyponatremia / etiology*
  • Hyponatremia / physiopathology
  • Inappropriate ADH Syndrome / etiology
  • Inappropriate ADH Syndrome / physiopathology
  • Ipilimumab
  • Melanoma / drug therapy
  • Pituitary Diseases / chemically induced*
  • Pituitary Diseases / complications*
  • Pituitary Diseases / physiopathology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Ipilimumab